Literature DB >> 27226081

Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation.

Lenka Hošková1, Janka Franekova2, Ivan Málek1, Josef Kautzner1, Ondřej Szárszoi1, Antonín Jabor2, Marian Pinďák1, Ondřej Viklický3, Vojtěch Melenovský1.   

Abstract

BACKGROUND Acute kidney injury (AKI) is a risk factor for adverse hospital outcomes in recipients of a heart transplantation (HTx). Timely recognition of AKI is crucial for the initiation of proper treatment. We hypothesized that serum or urine biomarkers can predict AKI. MATERIAL AND METHODS In this prospective study we evaluated 117 consecutive patients after HTx. AKI was defined as an increase of the serum creatinine level by ≥50% or a worsening of the renal function requiring renal replacement therapy during the first post-HTx week. We serially sampled serum cystatin C (S-cystatin C) as a marker of glomerular filtration and urinary neutrophil gelatinase-associated lipocalin (U-NGAL) as a marker of tubular damage. RESULTS A cohort of 30 patients (25.6%) fulfilled the criteria of AKI. S-cystatin C allowed the earliest separation between the AKI and non-AKI groups, with a significant difference present as soon as 3 h after surgery and it persisted on days 7, 10, and 30. The increase in S-cystatin C preceded the serum creatinine elevation by 4 days. In a multivariate analysis, S-cystatin C >1.6 mg/L at 3 h after HTx predicted AKI with OR 4.3 (95% CI: 1.6-11.5). U-NGAL was significantly higher at day 3 in the AKI group (p=0.003) and elevated S-cystatin C (≥2.54 mg/L on day 7) could predict 1-year mortality in these HTx recipients. CONCLUSIONS Our study showed that the measurement of S-cystatin C at 3 h after surgery may help to identify patients with high risk for renal complications. A persistent elevation of S-cystatin C also predicts 1-year mortality.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27226081     DOI: 10.12659/aot.896700

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  7 in total

Review 1.  Epidemiology, outcomes, and management of acute kidney injury in the vascular surgery patient.

Authors:  Charles Hobson; Nicholas Lysak; Matthew Huber; Salvatore Scali; Azra Bihorac
Journal:  J Vasc Surg       Date:  2018-06-28       Impact factor: 4.268

Review 2.  Perioperative Acute Kidney Injury: Risk Factors and Predictive Strategies.

Authors:  Charles Hobson; Rupam Ruchi; Azra Bihorac
Journal:  Crit Care Clin       Date:  2017-04       Impact factor: 3.598

3.  The value of cystatin C and urinary and serum neutrophil gelatinase-associated lipocalin during the perioperative period of renal transplantation.

Authors:  Feng Li; Linkun Hu; Xiaojun Zhao; Wenqing Ge; Hao Pan; Wei Zhang; Yufeng Jiang; Xu Xu; Jianquan Hou; Jinxian Pu
Journal:  Transl Androl Urol       Date:  2019-10

4.  Myo-inositol Oxygenase as a Novel Marker in the Diagnosis of Acute Kidney Injury.

Authors:  Cuma Mertoglu; Murat Gunay; Ali Gurel; Mehmet Gungor
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

5.  Acute Kidney Injury in Patients Undergoing Cardiac Transplantation: A Meta-Analysis.

Authors:  Charat Thongprayoon; Ploypin Lertjitbanjong; Panupong Hansrivijit; Anthony Crisafio; Michael A Mao; Kanramon Watthanasuntorn; Narothama Reddy Aeddula; Tarun Bathini; Wisit Kaewput; Wisit Cheungpasitporn
Journal:  Medicines (Basel)       Date:  2019-11-01

6.  Risk factors of renal replacement therapy after heart transplantation: a retrospective single-center study.

Authors:  Bingying Xie; Lei Fu; Yijin Wu; Xinfu Xie; Wenhao Zhang; Jihua Hou; Dinglin Liu; Ruizhao Li; Li Zhang; Chengbin Zhou; Jinsong Huang; Xinling Liang; Min Wu; Zhiming Ye
Journal:  Ann Transl Med       Date:  2022-03

7.  Evaluation of the effect of Retrograde Intrarenal Surgery with Myo-Inositol Oxygenase.

Authors:  Cuma Mertoglu; Aliseydi Bozkurt; Ercüment Keskin; Murat Gunay
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.